Washington, DC (December 18, 2025) – The American Pharmacists Association (APhA) participated in a White House ceremony marking the rescheduling of marijuana as a Schedule III drug. Marijuana’s Schedule I classification imposes strict regulatory requirements that make it difficult for researchers and scientists to obtain it for study. APhA believes that moving marijuana to Schedule III will help accelerate research into its medicinal applications and potentially lead to safer and more effective therapeutic uses.

Washington, DC (December 10, 2025)  — The American Pharmacists Association (APhA) is proud to announce that Thomas E. Menighan, BSPharm, MBA, ScD, has been selected as the 2026 Remington Honor Medal recipient. This accolade is widely recognized as the highest honor in the field of pharmacy. 

Washington, DC (December 4, 2025) The American Pharmacists Association (APhA) is deeply disappointed by today’s vote by the CDC’s Advisory Committee on Immunization Practices (ACIP) to remove the universal recommendation for administering the hepatitis B vaccine birth dose for infants born in the United States. This reversal rolls back a highly effective, evidence-based public health measure that has been in place since 1991.

Washington, DC (December 2, 2025) — The American Pharmacists Association (APhA) today announced a major legislative victory secured for pharmacists and the patients they serve. Working closely with bipartisan members of Congress and collaborating with other health care stakeholders, APhA successfully secured language in recently passed opioid use disorder (OUD) legislation that empowers pharmacists to play a greater role in combating the opioid crisis and expands their ability to provide life-saving care.